Personalized Medicine Startup Shuts Down

Everyone Medicines was founded on the story of Mila, a young girl with a fatal rare neurodegenerative condition. Her mother, Julia Vitarello, in a race against time, collaborated with Dr. Timothy Yu at Boston Children's Hospital to create "milasen," the first-ever drug tailored to a single individual. This groundbreaking "n-of-1" therapy showed promise in improving Mila's quality of life, sparking hope for a new class of hyper-personalized medicines. The company aimed to build a scalable business model for these unique treatments, focusing initially on antisense oligonucleotides (ASOs) for rare neurological diseases. The goal was to industrialize the process of creating custom drugs, a venture that attracted investments from major players like GV (formerly Google Ventures) and Khosla Ventures. The shutdown, however, highlights the immense challenge of commercializing these "n-of-1" therapies. A key factor appears to be the newly released FDA draft guidance for individualized treatments. According to sources familiar with the matter, the FDA's proposed pathway was perceived as not going far enough to make custom drugs commercially viable in the U.S., falling short of the more streamlined "process-based" approval the company was experiencing in a U.K. pilot program. This setback underscores a central debate in the life sciences: how to create sustainable business models for treatments targeting ultra-rare conditions. While the science to create individualized medicines is advancing rapidly, the regulatory and economic frameworks are still struggling to keep pace, leaving the future of "bespoke" treatments uncertain. For those interested in the life sciences, this story illuminates two distinct career paths. On one side are the tech-focused roles like bioinformatics and computational biology. Professionals in this area use computer science, statistics, and biology to analyze massive datasets, develop algorithms, and build the tools that make personalized medicine possible. An educational path here typically involves a strong foundation in computer science and biology, with many roles requiring a master's degree or Ph.D. On the other side are patient-facing roles, such as genetic counseling. Genetic counselors work directly with individuals and families, helping them understand complex genetic information and make informed healthcare decisions. This career requires a master's degree in genetic counseling and emphasizes skills in communication, empathy, and education, bridging the gap between the lab and the patient's life. A day in the life of a computational biologist might involve writing code, analyzing genomic data, and collaborating with researchers to identify potential drug targets. In contrast, a genetic counselor's day would be filled with patient consultations, explaining genetic test results, and providing emotional support and resources. Both are crucial to the advancement of personalized medicine, but they represent very different ways of contributing to the field.